Table 1.
Clinical and Demographic Data of Patients Included in the Study According to Trofile
| R5 | DM/X4 | Total | |
|---|---|---|---|
| Age* (years) | 45 (41–48) | 18 (13–40) | 39 (15–45) |
| Gender (% males) | 86 | 76 | 76 |
| TCD4* at collection (cells/mm3) | 226 (95–277) | 184 (94–372) | 218 (94–327) |
| Nadir TCD4* (cells/mm3) | 37 (17–79) | 35 (27–97) | 36 (23–108) |
| Viremia* at collection (log10/ml) | 3.43 (2.53–4.19) | 4.47 (3.59–4.92) | 4 (2.98–4.76) |
| Number of regimes* | 8 (7–9) | 6 (5–9) | 8 (5–9) |
| Time on ARV* (years) | 15 (13–16) | 16 (4–17) | 16 (13–17) |
| N (%) | 7 (28) | 17 (68) | 25a (100) |
a
One case of Trofile not reportable, reported as R5 by the IAL rule.
Patient characteristics according to Trofile result, R5 and dual/mixed or X4 tropism, including age at the time of collection, percentage of males, TCD4 counts at collection, and the nadir value, documented throughout follow-up, plasma viremia (viral load) at collection, number of different ARV combinations (regimens) used by the patient and the total time on ARV therapy in years, expressed as medians and 25th–75th IQR percentiles*, and the total number of cases in each group. ARV, antiretroviral.